eXmoor Pharma and UCL Form Strategic Partnership to Accelerate Cell and Gene Therapy Development
Key Insights
eXmoor Pharma (search) has established a strategic collaboration with University College London's Translational Research Office to accelerate cell and gene therapy (search) development from academic research to clinical application.
The partnership will provide UCL researchers with access to eXmoor's GMP manufacturing capabilities, regulatory expertise, and consultancy services to overcome technical and regulatory challenges that often delay CGT candidates.
The collaboration aims to create faster routes to clinical trial readiness by combining UCL's translational research expertise with eXmoor's over 20 years of consultancy experience and manufacturing capabilities.
eXmoor Pharma (search), the UK's only fully integrated cell and gene therapy (search) CDMO with embedded consultancy expertise, has formed a strategic collaboration with the Translational Research Office (TRO) at University College London (UCL) to accelerate the development of novel cell and gene therapies from academic research into clinical application.
The partnership addresses a critical bottleneck in the cell and gene therapy (search) development pipeline, where promising CGT candidates are often delayed by technical and regulatory challenges. By combining UCL's translational research expertise with eXmoor's consultancy, development and Good Manufacturing Practice (GMP) capabilities, the collaboration aims to create faster and more effective routes to clinical trial readiness.
Comprehensive Support Framework
Under the collaboration, UCL researchers will gain early access to a comprehensive suite of services designed to streamline the development process. This includes CMC consulting and regulatory strategy support, laboratory capacity and expertise in process and analytical development, and GMP manufacturing for early clinical studies. The partnership also provides cross-modality insight across viral vectors (search), autologous and allogeneic cell therapies (search), and RNA technologies (search).
The collaboration will support earlier and more efficient engagement between UCL innovators and eXmoor's multidisciplinary teams, helping to reduce the risk, cost and complexity of technology development. UCL researchers will benefit from structured early engagement opportunities including grant input, regular consultancy clinics, and joint events, all designed to bridge the gap between academic innovation and GMP readiness.
Industry Expertise Meets Academic Innovation
eXmoor brings over two decades of consultancy experience to its CGT manufacturing and commercialisation capabilities, acting as a partner for innovators scaling their CGT therapies. The company operates a purpose-built facility in Bristol, UK, and serves over 170 clients globally as a trusted partner for cell and gene therapy (search) innovators.
In exchange for providing access to its expertise and services, eXmoor will benefit from direct collaboration with UCL's translational researchers, enabling its teams to stay at the forefront of technological innovation and evolving CGT modalities. By working together from the earliest stages of development, eXmoor can align its capabilities with emerging innovations and foster scalable, GMP-ready solutions that reflect real clinical and commercial potential.
Leadership Perspectives
"The strength of the UK's academic science has always been clear but getting groundbreaking therapies from the lab to patients requires a collaborative approach," said Angela Osborne, Founder & Executive Chair of eXmoor Pharma (search). "This partnership with UCL TRO reflects our shared belief that supporting translational research with practical, GMP-ready solutions is the key to unlocking meaningful outcomes for patients. We're pleased to play a role in helping academic innovation become clinical reality."
Pamela Tranter, Head of the Translational Research Group at UCL Translational Research Office (search), emphasized UCL's commitment to innovation: "UCL is committed to driving innovation that transforms lives, with a world-leading pipeline of Advanced Therapy Medicinal Products (search) (ATMPs). Through this strategic partnership, we look forward to connecting UCL researchers with eXmoor's expertise, supporting closer collaboration with industry and the development of practical, scalable plans that could help realise therapeutic potential."
Translational Research Focus
The UCL Translational Research Office (search) serves as an integral part of UCL's established biomedical research ecosystem, supporting the translation of the university's world-class biomedical research into new therapies, diagnostics and medical devices that deliver patient benefit. Working in partnership with researchers and external collaborators, the TRO provides specialist knowledge to help advance discoveries along the development pathway and accelerate their journey from lab to market.
The collaboration represents a strategic approach to overcoming the challenges that often prevent promising academic discoveries from reaching patients, by providing practical, GMP-ready solutions that support the development of commercially viable therapies.